Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2018

Summarized information related to this collaboration is as follows:



Years Ended December 31	2018		2017		2016
Net product sales recorded by Merck	$	190	$	149	$	88
Merck’s profit share from sales in Bayer’s marketing territories	139		151		81
Total sales	329		300		169

Cost of sales ⁽¹⁾	216		99		133
Selling, general and administrative	35		27		26
Research and development	127		101		82

December 31			2018		2017
Receivables from Bayer included in Other current assets			$	32	$	33
Payables to Bayer included in Accrued and other current liabilities ⁽²⁾			—		350
Payables to Bayer included in Other Noncurrent Liabilities ⁽²⁾			375		—

⁽¹⁾ Includes amortization of intangible assets.

⁽²⁾Includes accrued milestone payments.

Summarized information related to this collaboration is as follows:



Year Ended December 31	2018
Alliance revenue	$	149

Cost of sales⁽¹⁾	39
Selling, general and administrative	13
Research and development ⁽²⁾	1,489

December 31	2018
Receivables from Eisai included in Other current assets	$	71
Payables to Eisai included in Accrued and other current liabilities ⁽³⁾	375
Payables to Eisai included in Other Noncurrent Liabilities ⁽³⁾	543

⁽¹⁾Represents amortization of capitalized milestone payments.

⁽²⁾Includes $1.4 billion related to the upfront payment and future option payments.

⁽³⁾Includes accrued milestone and option payments.

nt testing.

Summarized information related to this collaboration is as follows:



Years Ended December 31	2018		2017
Alliance revenue	$	187	$	20

Cost of sales ⁽¹⁾	93		4
Selling, general and administrative	48		1
Research and development ⁽²⁾	152		2,419

December 31	2018		2017
Receivables from AstraZeneca included in Other current assets	$	52	$	12
Payables to AstraZeneca included in Accrued and other current liabilities⁽³⁾	405		543
Payables to AstraZeneca included Other Noncurrent Liabilities ⁽³⁾	250		100

⁽¹⁾ Represents amortization of capitalized milestone payments.

⁽²⁾ Amount for 2017 includes $2.35 billion related to the upfront payment and future license option payments.

⁽³⁾ Includes accrued milestone and license option payments.